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Sleep apneaAbstract Background: Metabolic syndrome is a medical disorder that predisposes to cardiovascu-
lar diseases. Excessive daytime sleepiness (EDS) is a common finding in patients with metabolic
syndrome.
Aim: To assess the presence of EDS among subjects with metabolic syndrome and to find its
correlations with apnea hypopnea index (AHI), Hamilton depression rating score (HDRS), body
mass index (BMI), age and fasting plasma glucose (FPG).
Method: 76 patients with metabolic syndrome were evaluated for EDS by Epworth sleepiness
score (ESS) and for sleep apnea by polysomnography.
Results: 22 subjects (28.9%) had EDS, 37 subjects (48.7%) had sleep apnea and 28 subjects
(36.8%) had depression. ESS showed no significant association with AHI while it showed
significant associations with each of HDRS, BMI, age and FPG.
Conclusions: Other explanations of EDS in subjects with metabolic syndrome can be related to
obesity, depression, or diabetes rather than to sleep apnea. Subjects with metabolic syndrome
should be screened for EDS regardless of sleep apnea.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Metabolic syndrome is a combination of the medical disorders
that, when present together, increase the risk of developing
cardiovascular disease and diabetes. Some studies have shown
the prevalence in the USA to be an estimated 25% of the
population, and prevalence increases with age [1].Metabolic syndrome, also known as insulin resistance syn-
drome or syndrome X, is recognized as a constellation of obe-
sity, glucose intolerance, dyslipidemia, and hypertension. Over
the past several decades, there has been a substantial increase
in the prevalence of metabolic syndrome, coinciding with the
increased prevalence of obesity [2].
Obstructive sleep apnea (OSA) is a clinical condition char-
acterized by recurrent episodes of complete obstruction
(apnea) or partial obstruction (hypopnea) of the upper airway,
leading to increased negative intrathoracic pressure, sleep
fragmentation, and intermittent hypoxia during sleep [3].rculosis.
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to be 3–7% in men and 2–5% in women. Among patients
with a body mass index greater than 28, OSA is present in
41% [4,5].
OSA has implications beyond disrupted sleep. It is increas-
ingly recognized as an independent risk factor for cardiac, neu-
rologic, and peri-operative morbidities [6]. It is also associated
with high incidence of some psychiatric disturbances such as
depression [7].
Some studies showed that 50–60% of people who are obese
and patients with the metabolic syndrome have OSA [8]. The
prevalence of OSA is even higher in obese patients with dia-
betes mellitus [9].
Excessive daytime sleepiness may be related to the extent of
adiposity, the distribution of adiposity, or metabolic, inflam-
matory, physical, mental, or psychological disturbances expe-
rienced by obese subjects. It may be also related to the
increased incidence of OSA in these patients [10].
Excessive daytime sleepiness compromises quality of life
due to the impairment it causes in work performance, interper-
sonal relations, and cognitive and neuropsychological func-
tions, in addition to causing a higher risk of car accidents,
and metabolic and cardiovascular diseases [11–14].
So the presence of excessive daytime sleepiness in subjects
with metabolic syndrome has to be assessed and explained.
The aim of this study was to assess excessive daytime sleepiness
in subjects with metabolic syndrome and to find the correlation
between daytime sleepiness as measured by the Epworth sleepi-
ness scale and both apnea hypopnea index, Hamilton Depres-
sion Rating Scale, body mass index, waist circumference, age
and fasting plasma glucose (FPG).
Subjects and methods
Patients who presented to outpatient clinics in Tanta Univer-
sity Hospitals and had the diagnostic criteria of the metabolic
syndrome according to the International Diabetes Federation
(IDF) consensus worldwide definition [15] and who agreed to
share in the study were included. Study sample was taken with
a convenient sample technique until recruitment of 76 subjects
was achieved in a period of six months. The study protocol was
approved by the local ethics committee of Tanta Faculty of
Medicine and written consents were signed by all the
participants.
The IDF consensus worldwide definition of the metabolic
syndrome [15] 2006 is: Central obesity (defined as increased
waist circumference with ethnicity-specific values) and any
two of the following (NB: If BMI is >30 kg/m2, central
obesity can be assumed and waist circumference does not need
to be measured):
 Raised triglycerides: >150 mg/dL (1.7 mmol/L), or specific
treatment for this lipid abnormality.
 Reduced HDL cholesterol: <40 mg/dL (1.03 mmol/L) in
males, <50 mg/dL (1.29 mmol/L) in females, or specific
treatment for this lipid abnormality.
 Raised blood pressure (BP): systolic BP > 130 or diastolic
BP > 85 mmHg, or treatment of previously diagnosed
hypertension.
 Raised fasting plasma glucose (FPG): >100 mg/dL
(5.6 mmol/L), or previously diagnosed type 2 diabetes.Exclusion criteria: We excluded patients with thyroid or
other endocrinal disorders other than diabetes mellitus,
asthma, COPD, restrictive lung disease, lung cancer, sarcoido-
sis, chronic liver or kidney diseases, and previous psychiatric
diagnosis or who were on antidepressant medications. Patients
with alcohol or drug addiction, cerebral infarction, unstable
angina, myocardial infarction during the previous 3 months,
and congestive heart failure were also excluded.
The followings were carried for all participants:
 Thorough history taking: with special care to other
co-morbidities, drug use, smoking status, substance and
alcohol abuse.
 Examination: general and chest examination to exclude
patients with exclusion criteria, assess body mass index
(BMI), vital signs, and waist circumference.
 Routine laboratory tests: to help diagnosing metabolic
syndrome, and to exclude patients with exclusion criteria.
 Chest X ray postero–anterior view.
 Epworth sleepiness scale: was used to assess daytime sleepi-
ness. Patients rated the likelihood of falling asleep in eight
specific situations on a 0–3 scale, with 0 meaning no chance
at all of falling asleep, and 3 representing a high chance of
falling asleep. Thus, the scale goes from 0 to 24. A score of
ten suggests excessive daytime sleepiness [16].
 The Hamilton Depression Rating Scale (HDRS): it is an
inventory employed to detect and identify the intensity or
severity of the signs and symptoms of depression; 17 ques-
tions are divided into two categories. The first category con-
sists of nine questions scored on a five-point scale; the
second category consists of eight questions rated on a
three-point scale. The total score is computed reflecting
the degree of symptom severity. A score of >10 indicates
impairment [17].
 All patients underwent overnight polysomnography using
the Alice 5 Polysomnography System (Philips Respiron-
ics, Murraysville, PA) with Alice Sleepware Software. This
polysomnogram consisted of overnight recording of left and
right electrooculogram, chin electromyogram, left and right
tibialis anterior electromyogram, central and occipital
EEG, electrocardiogram, airflow measurement, body posi-
tion sensor, snoring sensor and microphone, respiratory
effort belt (abdominal and thoracic), and pulse oximetry.
The sleep study began around 11 pm and the duration of
the study was at least 5 h. The patients were instructed to
avoid sleeping during the daytime before the study and to
avoid alcohol, sedatives, hypnotics, and other medicines
affecting sleep.
Statistical analysis: It was performed with the Statistical
Package for Social Sciences (SPSS), version 16.0 (Chicago,
IL, USA). Data are presented as mean (±SD) values. Appro-
priate test of significance was used when needed. Significant
statistical difference was considered when p< 0.05.
Results
The study included 76 subjects with metabolic syndrome who
agreed to share in the study. Demographic, anthropometric
and clinical characteristics of the studied subjects are shown
in Table 1.
Table 1 Demographic, anthropometric and clinical charac-
teristics of the studied group.
Characteristics Study group (n= 76)
No. %
Age in years
43.03 ± 14.32
18– 15 19.7
30– 15 19.7
40– 16 21.1
50– 17 22.4
P60 13 17.1
Gender
Males 40 52.6
Females 36 47.4
BMI
33.8 ± 1.9 kg/m2
30–34.9 44 57.9
P35 32 42.1
Waist circumference
High risk 44 57.9
Low risk 32 42.1
ESS
8.3 ± 5.7
Positive 22 28.9
Negative 54 71.1
AHI
13.62 ± 14.2
Nil 39 51.3
Mild (5-) 8 10.5
Moderate (15-) 16 21.1
Severe (P30) 13 17.1
HDRS
15.34 ± 13.77
Positive 28 36.8
Negative 58 63.2
FPG
158.89 ± 44.8 mg%
>100 mg/dL 45 59.2
6100 mg/dL 31 40.8
BMI: body mass index. ESS: Epworth sleepiness score. AHI:
Apnea hypopnea index. HDRS: Hamilton depression rating scale.
FPG: Fasting plasma glucose.
Table 2 Epworth sleepiness score (ESS) in relation to
demographic, anthropometric and clinical characteristics of
the studied group.
Characteristics Epworth sleepiness score (ESS) Test of
significance
Positive
(n= 22)
Negative
(n= 54)
v2
p
No. % No. %
Age in years
<40 4 18.2 26 48.1 5.875
P40 18 81.8 28 51.9 0.015*
Gender
Males 12 54.5 28 51.9 0.045
Females 10 45.5 26 48.1 0.831
BMI
30–34.9 6 27.3 38 70.4 11.911
P35 16 72.7 16 29.6 0.001*
Waist circumference
High risk 17 77.3 27 50 4.77
Low risk 5 22.7 27 50 0.029*
AHI
Nil 10 45.5 29 53.7
Mild 2 9.1 6 11.1 0.88
Moderate 5 22.7 11 20.4 0.83
Severe 5 22.7 8 14.8
HDRS
Positive 13 59.1 15 27.8 6.587
Negative 9 40.9 39 72.2 0.010*
FPG
>100 mg/dL 17 77.3 28 51.9 4.183
6100 mg/dL 5 22.7 26 48.1 0.041*
BMI: body mass index. AHI: Apnea hypopnea index. HDRS:
Hamilton depression rating scale. FPG: Fasting plasma glucose.
* Significant statistical difference.
Table 3 Correlations between AHI and other studied
parameters.
Correlations between AHI and r p
HDRS 0.47 <0.001*
BMI 0.77 <0.001*
Waist circumference 0.755 <0.001*
Age 0.404 <0.001*
FPG 0.364 0.001*
BMI: body mass index. AHI: Apnea hypopnea index. HDRS:
Hamilton depression rating scale. FPG: fasting plasma glucose.
* Significant.
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cant association with apnea hypopnea index (AHI) while it
showed significant association with both HDRS, BMI and
waist circumference, age and fasting plasma glucose (FPG)
(p< 0.05) (Table 2).
AHI showed significant positive correlations with HDRS,
BMI and waist circumference, age and FPG (Table 3).
It was noticed that AHI values in subjects having excessive
daytime sleepiness and those without excessive daytime sleepi-
ness were 17.3 ± 15.8 and 12.1 ± 13.4 respectively without
any statistically significant difference (t= 1.35 and p= 0.19).
Discussion
This study has shown that Epworth sleepiness score (ESS) in
subjects with metabolic syndrome was 8.263 ± 5.7. Thenormal community mean (±standard deviation) ESS is 4.6
± 2.8 [10]. This means that subjects with metabolic syndrome
have more excessive daytime sleepiness (EDS) than the general
population. Also, we found that about half of subjects with
metabolic syndrome have polysomnographic evidence of sleep
apnea with a mean apnea hypopnea index (AHI) of 13.62
events per hour.
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found in 60% of obstructive sleep apnea (OSA) patients [18],
while it was found in 51.2% of OSA patients by Bonsignore
et al. [19]. Drager et al. found the prevalence of sleep apnea
among metabolic syndrome subjects to be 60% [8].
Visceral obesity/insulin resistance may be the principal
culprit leading to sleep apnea, which, in turn, may accelerate
these metabolic abnormalities, possibly through progressive
elevation of stress hormones and cytokines. Furthermore, day-
time sleepiness is frequently associated with obesity, diabetes
type 2, and insulin resistance independent of sleep-disordered
breathing [20].
Both metabolic syndrome and sleep apnea may be mecha-
nistically linked through a number of possible pathways.
OSA is associated with alterations in the hypothalamic–pitui
tary–adrenal axis that may promote the metabolic syndrome.
The hypoxia associated with sleep apnea triggers an oxidative
stress that may promote development of metabolic syndrome.
Multiple inflammatory markers and mediators, including
nuclear factor kappa B (NF-jB), C-reactive protein (CRP),
tumor necrosis factor a (TNF-a), and interleukin 6 (IL-6),
are elevated in patients with OSA and may play a role in the
development of metabolic syndrome [21].
In our study, ESS showed no significant association with
AHI. Also, AHI showed no significant difference between sub-
jects having EDS and those without. These findings may sug-
gest that EDS in subjects with metabolic syndrome may not
be caused by sleep apnea and other factors may cause it.
Daytime sleepiness is a critical symptom of sleep apnea but
is not pathognomonic. A number of sleep, medical, and mental
diseases and disorders include this symptom [20]. It is known
also that traditional risk factors for OSA such as EDS may
not be present in a significant proportion of obese patients [22].
Bixler et al. reported that when diagnosing a case with a
complaint of EDS, sleep disturbance (e.g., due to sleep apnea)
should not be considered the only cause. It appears that EDS is
more strongly associated with mood factors as well as meta-
bolic factors rather than with sleep-disordered breathing [23].
Dixon et al. found that there was no significant relationship
between ESS score and AHI in obese individuals [10]. They
concluded that EDS and obstructive sleep apnea are common
disorders in obese subjects but seem to be largely unrelated. On
the other hand, Bonsignore et al. found no difference in EDS
between patients with and without metabolic syndrome [19].
In a trial to find an alternative cause of EDS in our studied
subjects, we tried to find an association between both ESS and
AHI and the other studied parameters. We found that both
ESS and AHI independently had significant associations with
BMI, waist circumference, FPG and age. So we can attribute
EDS in subjects with metabolic syndrome to one or more of
the following factors: obesity, depression, advanced age and
presence of diabetes rather than having sleep apnea.
Metabolic syndrome, insulin resistance, and obesity were
found to be stronger determinants of sleepiness compared to
apnea/hypopnea index [20].
Bixler et al. found that depression was the most significant
risk factor for EDS followed by BMI, age, typical sleep
duration, diabetes, smoking, and finally sleep apnea [23]. They
suggested that patients with a complaint of EDS should be
thoroughly assessed for depression and obesity/diabetes
independent of whether sleep-disordered breathing is present.Barcelo et al. found that OSA patients with EDS had higher
plasma levels of glucose and evidence of insulin resistance com-
pared with patients without EDS or healthy controls [24].
Dixon et al. reported that EDS was related to older age,
male gender, smoking, type 2 diabetes, symptoms of depres-
sion, and poor quality of life [19]. Depression is a common
finding in patients with OSA who should be screened carefully
for depressive disorders [7].
The inflammatory cytokines TNF-a, interleukin-1b (IL-1b),
and IL-6 are involved in physiological sleep regulation, and
that their increased secretion or exogenous administration to
humans is associated with sleepiness and fatigue [25,26].
Limitations of the study
 ESS does not assess sleepiness objectively, and lack of mul-
tiple sleep latency test data is a limitation of our study. Any-
way, the widespread use of ESS and its strong validation
through many published studies encouraged us to use it.
 This study is cross-sectional, and thus, causation cannot be
directly tested.
Conclusions and recommendations
Lack of association between excessive daytime sleepiness
(EDS) and AHI in subjects with metabolic syndrome was
noticed in our study, so other explanations of EDS in this cat-
egory of patients can be related to obesity, depression, or dia-
betes rather than to sleep apnea. Subjects with metabolic
syndrome should be screened for EDS regardless of sleep
apnea. Weight reduction and proper blood glucose control
can reduce the occurrence of EDS in patients with metabolic
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